DAP-5, a Novel Homolog of Eukaryotic Translation Initiation Factor 4G Isolated As a Putative Modulator of Gamma Interferon-induced Programmed Cell Death
Overview
Affiliations
A functional approach to gene cloning was applied to HeLa cells in an attempt to isolate cDNA fragments which convey resistance to gamma interferon (IFN-gamma)-induced programmed cell death. One of the rescued cDNAs, described in this work, was a fragment of a novel gene, named DAP-5. Analysis of a DAP-5 full-length cDNA clone revealed that it codes for a 97-kDa protein that is highly homologous to eukaryotic translation initiation factor 4G (eIF4G, also known as p220). According to its deduced amino acid sequence, this novel protein lacks the N-terminal region of eIF4G responsible for association with the cap binding protein eIF4E. The N-terminal part of DAP-5 has 39% identity and 63% similarity to the central region of mammalian p220. Its C-terminal part is less homologous to the corresponding region of p220, suggesting that it may possess unique functional properties. The rescued DAP-5 cDNA fragment which conveyed resistance to IFN-gamma-induced cell death was expressed from the vector in the sense orientation. Intriguingly, it comprised part of the coding region which corresponds to the less conserved C-terminal part of DAP-5 and directed the synthesis of a 28-kDa miniprotein. The miniprotein exerted a dual effect on HeLa cells. Low levels of expression protected the cells from IFN-gamma-induced programmed cell death, while high levels of expression were not compatible with continuous cell growth. The relevance of DAP-5 protein to possible changes in a cell's translational machinery during programmed cell death and growth arrest is discussed.
Non-canonical mRNA translation initiation in cell stress and cancer.
Mahe M, Rios-Fuller T, Katsara O, Schneider R NAR Cancer. 2024; 6(2):zcae026.
PMID: 38828390 PMC: 11140632. DOI: 10.1093/narcan/zcae026.
Multimodal stimulation screens reveal unique and shared genes limiting T cell fitness.
Lin C, Levy P, Alflen A, Apriamashvili G, Ligtenberg M, Vredevoogd D Cancer Cell. 2024; 42(4):623-645.e10.
PMID: 38490212 PMC: 11003465. DOI: 10.1016/j.ccell.2024.02.016.
Meril S, Muhlbauer Avni M, Lior C, Bahlsen M, Olender T, Savidor A Oncogene. 2024; 43(15):1098-1112.
PMID: 38388710 PMC: 10997518. DOI: 10.1038/s41388-024-02981-x.
Loss-of-function cancer-linked mutations in the EIF4G2 non-canonical translation initiation factor.
Meril S, Bahlsen M, Eisenstein M, Savidor A, Levin Y, Bialik S Life Sci Alliance. 2023; 7(3).
PMID: 38129098 PMC: 10746786. DOI: 10.26508/lsa.202302338.
Malik I, Tseng Y, Wieland C, Green K, Zheng K, Calleja K Neurobiol Dis. 2023; 184:106212.
PMID: 37352983 PMC: 11149892. DOI: 10.1016/j.nbd.2023.106212.